Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer

(2018) Herbert H. Loong et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).

(2018) Myung-Ju Ahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy

(2018) Jun Lu et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

METCopy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis ofEGFR-mutant Lung Cancer

(2017) Shigeki Nanjo et al.   MOLECULAR CANCER THERAPEUTICS

The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer

(2017) Dan Zhao et al.   Scientific Reports

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

(2016) Yang-Si Li et al.   Journal of Thoracic Oncology

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

(2015) Y. Kobayashi et al.   CLINICAL CANCER RESEARCH

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

(2015) Petra Hoffknecht et al.   Journal of Thoracic Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

(2015) Leticia De Mattos-Arruda et al.   Nature Communications

Targeted therapy in brain metastasis

(2012) Riccardo Soffietti et al.   CURRENT OPINION IN ONCOLOGY

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

(2012) James Chih-Hsin Yang et al.   LANCET ONCOLOGY